John Hennessy, Associate Principal at Payer Sciences, shared a post on LinkedIn:
“This real world study isn’t a US-based study, but the reasons for discontinuation certainly seem universal enough.
It’s a pretty high discontinuation rate for a fixed duration therapy. Perhaps someone is doing similar work in the US?”
Title: Treatment Discontinuation in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated with Lutetium-177 (177Lu)–PSMA-617: A Retrospective Real-World Study
Authors: Mohammad Hadi Samadi, Amirreza Shamshirgaran, Pegah Sahafi, Haniye Elahifard, Ghasemali Divband, Kamran Aryana, Emran Askari
More posts featuring John Hennessy.